Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) recent gain occurred on high volume with 1682024 contracts changing hands on 14-Mar-19. That’s greater from its daily average of 898580 contracts. The first sale was made at $0.74 but later the stock became weaker, and closed with a gain of 22.54%. It was last traded at $0.87 apiece.

Sunesis Pharmaceuticals, Inc. (SNSS): Outperform Candidate With 388.51% Upside Potential

Sunesis Pharmaceuticals, Inc. is maintained at an average outperform rating by 4 stock analysts, and there are at least 0.48% of shares outstanding that are currently legally short sold. The shares went up by 70.76% in value last month. Year-to-date it jumped 109.29%. Analysts are turning out to be more optimistic than before, with 2 of analysts who cover Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) advice adding it to buy candidate list. Wall Street experts also assign a $4.25 price target on Sunesis Pharmaceuticals, Inc., pointing towards a 388.51% rally from current levels. The stock is trading for about -79.58% less than its 52-week high.

SNSS Adds 20.83% In A Week

This company shares (SNSS) so far managed to recover 335% since collapsing to its 52-week low. Over a week, it has seen its stock price volatility to stay at 15.97% while widening the period to a month, volatility was 9.93%. The share price has already crossed its 20 days moving average, floating at a distance of 53.24% and sits 59.42% higher versus its 50 days moving average. When looking at the past five sessions, the stock returned 20.83% gains and is down by -40.84% compared with its 200-day moving average. Also, Sunesis Pharmaceuticals, Inc. (SNSS) needs to overturn a -79.51% decrease it experienced over the past twelve months.

Leap Therapeutics, Inc. (NASDAQ:LPTX) Consensus Call At 0

As regular trading ended, Leap Therapeutics, Inc. (LPTX) stock brought in a -$0.12 drop to $1.85. The day started at a price of $1.99 but then traded as high as $2.03 before giving part of the gains back. As for this week, analysts appear content to stick with their bright outlook with the consensus call at 0. Leap Therapeutics, Inc. is given 1 buy-equivalent recommendations, 0 sells and 0 holds. The company shares sank -81.95% from their peak of $10.25 and now has a $33.3 million market value of equity.

Leap Therapeutics, Inc. Could Grow 593.51% More

LPTX’s mean recommendation on Reuter’s scale presents no change from 1.67 thirty days ago to 1.67 now, which indicates a buy consensus from the analyst community. They see Leap Therapeutics, Inc. (LPTX) price hitting a mean target of $12.83 a share, meaning the stock still has potential that could lift the price another 593.51% . Also, the recent close suggests the stock is underpriced by 872.97% compared to the most bullish target.

Leap Therapeutics, Inc. (LPTX) Returns -7.5% This Year

The company had seen its current volume reaching at 1142730 shares in the last trade. That compares with the recent volume average of 2857680. At the close of regular trading, its last week’s stock price volatility was 9.07% which for the month reaches 18.71%. Leap Therapeutics, Inc. dipped to as low as $1.81 throughout the day and has returned -7.5% in this year. At one point in the past year, the shares traded as low as $1.35 but has recovered 37.04% since then. [T4]